男性不妊症のアジア太平洋市場2020-2026:治療別(生殖補助医療・精索静脈瘤手術、投薬)、検査別、地域別

◆英語タイトル:Asia Pacific Male Infertility Market By Treatment (Assisted Reproductive Technology & Varicocele Surgery and Medication), By Test (DNA Fragmentation Technique, Oxidative Stress Analysis, Computer Assisted Semen Analysis, Microscopic Examination, Sperm Agglutination, Sperm Penetration Assay and Other Tests), By Country, Industry Analysis and Forecast, 2020 - 2026
◆商品コード:KBV20OCT176
◆発行会社(リサーチ会社):KBV Research
◆発行日:2020年6月30日
◆ページ数:73
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:中国、日本、インド、韓国、シンガポール、マレーシア
◆販売価格オプション(消費税別)
Single User(1名様利用)USD1,500 ⇒換算¥162,000見積依頼/購入/質問フォーム
Global License(法人利用)USD2,520 ⇒換算¥272,160見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKBV Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
KBV Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本市場調査レポートでは、男性不妊症のアジア太平洋市場について、市場範囲・調査手法、市場概要、治療別(生殖補助医療・精索静脈瘤手術、投薬)分析、検査別分析、地域別分析、企業概要などを総合的、多面的に調査・分析しました。
・市場範囲・調査手法
・市場概要
・男性不妊症のアジア太平洋市場規模:治療別(生殖補助医療・精索静脈瘤手術、投薬)
・男性不妊症のアジア太平洋市場規模:検査別
・男性不妊症のアジア太平洋市場規模:地域別
・企業概要
【レポートの概要】

The Asia Pacific Male Infertility Market would witness market growth of 8.9% CAGR during the forecast period (2020-2026).

One of the key causes causing male infertility is sperm heterogeneity of DNA. Male infertility is a heterogeneous group of disorders, known causes account for only 30-50 percent, and unknown cause (idiopathic) is the rest. Infertility affects about 15 percent of people of reproductive age, and the male problem alone involves about 40 percent of the problems.

Tobacco smoke contains approximately 4,000 compounds, like alkaloids, nitrosamines, and inorganic molecules, and some of these are reactive oxygen or nitrogen species. A positive and significant association has been identified between active smoking and sperm DNA fragmentation and also axonemal damage. Smoking is often associated with a decreased sperm count. Smoking is considered to enhance spermatogenesis by increasing the production of norepinephrine, which increases the conversion of testosterone to estrogen causing decreased testosterone levels.
Sperm agglutination refers to the amount of sperm stuck together in the sample given. When evaluating a fertility test result, the percentage assigned to sperm agglutination is the percentage of sperm stuck together in the sample. For example, if the semen sample had only half the sperm sticking together, the report would read only 50 percent sperm agglutination.

Based on Treatment, the market is segmented into Assisted Reproductive Technology & Varicocele Surgery and Medication. Based on Test, the market is segmented into DNA Fragmentation Technique, Oxidative Stress Analysis, Computer Assisted Semen Analysis, Microscopic Examination, Sperm Agglutination, Sperm Penetration Assay and Other Tests. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include Sanofi S.A., Bayer AG, Cadila Healthcare Ltd. (Zydus Cadila), Endo International PLC, Aytu BioScience, Inc., Vitrolife AB, SCSA Diagnostics, Inc., Andrology Solutions Limited, Halotech DNA SL, and Intas Pharmaceutical Ltd.

Scope of the Study
Market Segmentation:

By Treatment
• Assisted Reproductive Technology & Varicocele Surgery and
• Medication

By Tests
• DNA Fragmentation Technique
• Oxidative Stress Analysis
• Computer Assisted Semen Analysis
• Microscopic Examination
• Sperm Agglutination
• Sperm Penetration Assay and
• Other Tests

By Country
• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Companies Profiled
• Sanofi S.A.
• Bayer AG
• Cadila Healthcare Ltd. (Zydus Cadila)
• Endo International PLC
• Aytu BioScience, Inc.
• Vitrolife AB
• SCSA Diagnostics, Inc.
• Andrology Solutions Limited
• Halotech DNA SL
• Intas Pharmaceutical Ltd.

Unique Offerings from KBV Research
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

【レポートの目次】

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Male Infertility Market, by Treatment
1.4.2 Asia Pacific Male Infertility Market, by Tests
1.4.3 Asia Pacific Male Infertility Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Male Infertility Market by Treatment
3.1 Asia Pacific Assisted Reproductive Technology and Varicocele Surgery Market by Country
3.2 Asia Pacific Medication Market by Country
Chapter 4. Asia Pacific Male Infertility Market by Test
4.1 Asia Pacific DNA Fragmentation Technique Market by Country
4.2 Asia Pacific Oxidative Stress Analysis Market by Country
4.3 Asia Pacific Computer Assisted Semen Analysis Market by Country
4.4 Asia Pacific Microscopic Examination Market by Country
4.5 Asia Pacific Sperm Agglutination Market by Country
4.6 Asia Pacific Sperm Penetration Assay Market by Country
4.7 Asia Pacific Other Test Market by Country
Chapter 5. Asia Pacific Male Infertility Market by Country
5.1 India Male Infertility Market
5.1.1 India Male Infertility Market by Treatment
5.1.2 India Male Infertility Market by Test
5.2 China Male Infertility Market
5.2.1 China Male Infertility Market by Treatment
5.2.2 China Male Infertility Market by Test
5.3 Japan Male Infertility Market
5.3.1 Japan Male Infertility Market by Treatment
5.3.2 Japan Male Infertility Market by Test
5.4 South Korea Male Infertility Market
5.4.1 South Korea Male Infertility Market by Treatment
5.4.2 South Korea Male Infertility Market by Test
5.5 Singapore Male Infertility Market
5.5.1 Singapore Male Infertility Market by Treatment
5.5.2 Singapore Male Infertility Market by Test
5.6 Malaysia Male Infertility Market
5.6.1 Malaysia Male Infertility Market by Treatment
5.6.2 Malaysia Male Infertility Market by Test
5.7 Rest of Asia Pacific Male Infertility Market
5.7.1 Rest of Asia Pacific Male Infertility Market by Treatment
5.7.2 Rest of Asia Pacific Male Infertility Market by Test
Chapter 6. Company Profiles
6.1 Sanofi S.A.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 Bayer AG
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.3 Cadila Healthcare Ltd. (Zydus Cadila)
6.3.1 Company Overview
6.3.1 Financial Analysis
6.3.2 Regional Analysis
6.3.3 Research & Development Expense
6.4 Endo International PLC
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental Analysis
6.4.4 Research & Development Expense
6.5 Aytu BioScience, Inc.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Regional Analysis
6.5.4 Research & Development Expenses
6.5.5 Recent strategies and developments:
6.5.5.1 Acquisition and Mergers:
6.5.5.2 Partnerships, Collaborations, and Agreements:
6.6 Vitrolife AB
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional Analysis
6.6.4 Research & Development Expenses
6.6.5 Recent strategies and developments:
6.6.5.1 Partnerships, Collaborations, and Agreements:
6.7 SCSA Diagnostics, Inc.
6.7.1 Company Overview
6.8 Andrology Solutions Limited
6.8.1 Company Overview
6.9 Halotech DNA SL6.9.1 Company Overview
6.1 Intas Pharmaceutical Ltd.
6.10.1 Company Overview



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[男性不妊症のアジア太平洋市場2020-2026:治療別(生殖補助医療・精索静脈瘤手術、投薬)、検査別、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆